Taeun Chang, M.D., is a neurologist in the division of Neurophysiology, Epilepsy and Critical Care at Children's National Health System. She also serves as the Director of the Neonatal Neurology and Neonatal Neurocritical Care Program.
As Director of the Neonatal Neurology and Neonatal Neurocritical Care Program, Dr. Chang’s goals are to expand and support clinical and basic science research in neonatal brain injuries and neonatal neurotherapeutics. Dr. Chang successfully created a neonatal neurocritical care (NNCC) service and an outpatient neonatal neurology clinic program in 2004. The NNCC service is composed of four dedicated neonatal neurologists and is consulted on over 250 infants each year in our 54-bed state-of-the-art Level IV NICU (one-third of all NICU admissions). In conjunction with the NICU, Dr. Chang established the Children’s National neonatal cooling protocol and program in 2006. Children’s National has cooled over 300 newborns to-date. Most recently, Dr. Chang was the principal investigator for Phase I/II, Phase II and Phase III clinical trials for Erythropoietin as a neuroprotective agent in neonates led by UCSF (Dr. Yvonne Wu).
Doctors Chang and Tammy N. Tsuchida have established an internationally-renowned neonatal neuromonitoring unit with four digital video EEG monitors in the NICU and bedside remote EEG access to each NICU bed. The NNCC service performs more than 400 prolonged continuous video-EEGs per year in our NICU (over 3,000 continuous EEG recordings since 2006); identifies more than 60 newborns per year with seizures as a result of hypoxic ischemic encephalopathy, perinatal strokes, cerebral dysgenesis, infection, inborn errors of metabolism or infantile epilepsy disorders; led national committees to establish neonatal EEG monitoring guidelines and terminologies; and collaborates on multiple national study groups for neonatal EEG, seizures and seizure treatment trials.
Dr. Chang and her colleagues in Neurology, Neonatology, Neuroradiology and Fetal Neurology are working on advancing the frontiers of neonatal neurointensive care and examining the antecedents for their brain injury or malformations. This age group has been largely ignored for neurologic therapies but is the leading age group for cerebral palsy and neurodevelopmental sequelae, a growing burden on society in general. Members of the program are actively involved in understanding the types and causes of neurologic injury in premature and term newborns, establishing clinical guidelines and pathways, promoting neonatal neuroprotective treatments and advancing the frontiers of this new subspecialty within child neurology.
Dr. Chang was raised and primarily educated in the Washington, D.C., metropolitan area. Her interest in neuroscience and medicine began when she attended the Montgomery Blair High School Magnet Program for Math, Science & Computer Science and continued on through M.I.T., spending summers conducting research with a neurosurgeon at Children’s National and George Washington University School of Medicine when she decided to pursue Child Neurology. She completed her pediatric residency at Children’s Hospital of Pittsburgh before returning to Children’s National for her child neurology fellowship.